Genix Pharmaceuticals Corp.

Recent News

  • Genix Pharmaceuticals Corporation Announces the Extension of Payment Terms for the Acquisitions of Rights to Renochlor(R), Sucanon(R) and Flu-x(TM)

    Vancouver, British Columbia--(Newsfile Corp. - June 30, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company"), announces that the Company and Canagen Pharmaceuticals Inc. ("Canagen") have mutually agreed to extend the closing dates for the payment terms ("Payment Terms") for the sole and exclusive distribution, sales and marketing rights and interest, excluding intellectual property rights, to certain nutraceutical products marketed and distributed under the brand names Renochlor® and Sucanon® as outlined in our news release...

    2020-06-30 8:53 PM EDT
  • Genix Pharmaceuticals Corporation Announces Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) (the "Company"), is pleased to announce a non-brokered private placement (the "Private Placement") for total gross proceeds of up to $562,500, subject to a 15% over-allotment option. The Private Placement will consist of up to 3,750,000 units (excluding any over-allotment) of the Company (each a "Unit") at a price of $0.15 per Unit. Each Unit will consist of one common share of the Company (a "Share")...

    2020-06-22 12:10 PM EDT
  • Genix Pharmaceuticals Corporation Enters into a Definitive Agreement to Acquire Global Rights to Flu-X(R)

    Vancouver, British Columbia--(Newsfile Corp. - March 27, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX)("GENIX" or the "Company"), announces that it has entered into an agreement, dated for reference March 24, 2020 (the "Agreement"), with Canagen Pharmaceuticals Inc. ("Canagen") pursuant to which, subject to acceptance of the TSX Venture Exchange ("TSXV"), the Company has agreed to purchase the sole and exclusive global distribution, sales and marketing rights and interest (the "Global Rights") for Flu-X®, a novel and proprietary, anti-viral, anti-flu...

    2020-03-27 9:00 AM EDT
  • Genix Pharmaceuticals Corporation Completes Purchase of Rights to 30 Ophthalmic Generic Drugs and Product Dossiers

    Vancouver, British Columbia--(Newsfile Corp. - February 14, 2020) - Genix Pharmaceuticals Corp. (TSXV: GENX) ("GENIX" or the "Company"), announces that it has completed the acquisition (the "Acquisition") of 30 World Health Organization approved ophthalmic drugs and product dossiers as stated in its press release dated December 23, 2019. Having received final acceptance to the Acquisition from the TSX Venture Exchange ("TSXV"), the Company issued 15,000,000 common shares to the shareholders of Canagen Pharmaceuticals Inc. to complete the Acquisition. The shares...

    2020-02-14 4:00 AM EST
  • Genix Acquires Exclusive Rights to SUCANON(R) and RENOCHLOR(R)

    Vancouver, British Columbia--(Newsfile Corp. - January 14, 2020) - Genix Pharmaceuticals Corp. (TSXV: GENX) ("GENIX" or the "Company"), announces that it has entered into an Acquisition Agreement dated for reference January 10, 2020 (the "Agreement") with Canagen Pharmaceuticals Inc. ("Canagen") pursuant to which, subject to acceptance of the TSX Venture Exchange ("TSX-V"), the Company has agreed to purchase sole and exclusive distribution, sales and marketing rights and interest (the "Rights") for Canada, (excluding intellectual property rights) for an initial term...

    2020-01-14 2:42 PM EST
  • Genix Pharmaceuticals Corporation Agrees To Purchase 30 Ophthalmic Generic Drug Dossiers And Enters Into LOI To Acquire 2 Additional Nutraceutical Products

    Vancouver, British Columbia--(Newsfile Corp. - December 23, 2019) - Genix Pharmaceuticals Corp. (TSXV: GENX) ("GENIX" or the "Company"), announces that the Company has entered into an Acquisition Agreement dated for reference September 19, 2019 (the "Agreement") and executed October 9, 2019 with Canagen Pharmaceuticals Inc. ("Canagen") pursuant to which, subject to acceptance of the TSX Venture Exchange ("TSXV"), the Company has agreed to purchase thirty (30) World Health Organization approved generic prescription ophthalmic drugs (the "Ophthalmic Drugs") and their...

    2019-12-23 7:13 PM EST
  • ALTA Announces Name Change to Genix Pharmaceuticals Corporation

    Vancouver, British Columbia--(Newsfile Corp. - June 18, 2019) - Alta Natural Herbs & Supplements Ltd. (TSXV: AHS) ("ALTA" or the "Company") is pleased to announce that it will be changing its Corporate name to Genix Pharmaceuticals Corporation effective on the commencement of trading Friday, June 21, 2019. The Company's common shares will trade on the TSX Venture Exchange under the new name and new stock symbol "GENX" on June 21, 2019. The name change, approved at last year's AGM, will...

    2019-06-18 6:43 PM EDT
  • Alta Natural Herbs & Supplements Appoints Board Member

    Vancouver, British Columbia--(Newsfile Corp. - June 5, 2019) - Alta Natural Herbs & Supplements (TSXV: AHS) (The "Company" or "ALTA") announces Dr. Conny Lin, PhD., has joined the Board of Directors of the Company effective immediately.Dr. Lin is a neuroscientist, a policy maker, and a veteran in board governance and government funding acquisition. She has started and led numerous organizations in various sectors, spearheading operations, human resources, R&D, and public relations. Dr. Lin worked briefly as a territory manager for...

    2019-06-05 4:27 PM EDT